NASDAQ:CLVS

Clovis Oncology Price Target, Predictions & Analyst Ratings

$4.86
-0.06 (-1.22 %)
(As of 08/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.73
$4.96
50-Day Range
$4.76
$6.54
52-Week Range
$4.08
$11.10
Volume3.07 million shs
Average Volume8.99 million shs
Market Capitalization$508.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Clovis Oncology (NASDAQ:CLVS) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Their average twelve-month price target is $6.67, predicting that the stock has a possible upside of 37.17%. The high price target for CLVS is $12.00 and the low price target for CLVS is $3.00. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
TypeToday30 Days Ago90 Days Ago180 Days Ago
CLVS Consensus Rating: HoldHoldHoldHold
CLVS Consensus Rating Score: 2.002.002.002.00
CLVS Analyst Ratings: 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
CLVS Consensus Price Target: $6.67$6.67$6.67$9.20
CLVS Price Target Upside: 37.17% upside34.59% upside34.59% upside51.21% upside

Clovis Oncology (NASDAQ:CLVS) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Clovis Oncology (NASDAQ:CLVS) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetDetails
5/5/2021HC Wainwright
Lower Price TargetBuy$13.00 ➝ $12.00
11/6/2020SVB Leerink
Lower Price TargetUnderperform$4.00 ➝ $3.00
11/5/2020Piper Sandler
Lower Price TargetNeutral$6.00 ➝ $5.00
11/1/2020JPMorgan Chase & Co.
Reiterated RatingHold
4/20/2020Royal Bank of Canada
Reiterated RatingBuy$17.00
4/19/2020Bank of America
DowngradeNeutral ➝ Underperform
11/27/2019Evercore ISI
DowngradeOutperform ➝ In-Line
10/31/2019Piper Jaffray Companies
Lower Price TargetNeutral$11.00 ➝ $4.00
8/2/2019G.Research
J. He
Reiterated RatingBuy
8/2/2019Barclays
Gena Wang
Set Price TargetBuy$36.00
8/2/2019Gabelli
J. He
Reiterated RatingBuy
8/1/2019Guggenheim
DowngradeBuy ➝ Neutral
5/29/2019The Goldman Sachs Group
DowngradeNeutral ➝ Sell$17.00 ➝ $15.00
5/15/2019Credit Suisse Group
Reiterated RatingBuy$29.00
4/15/2019SunTrust Banks
Lower Price TargetBuy$28.00
10/30/2018Oppenheimer
Leah R. Cann
Reiterated RatingHold
(Data available from 8/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 8/3/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.